The molecular determinants regulating redox signaling in diabetic endothelial cells
Frontiers in Pharmacology · 01.04.2025 · 16
DOI: 10.3389/fphar.2025.1563047 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 01.04.2025. Verfasst von Swayam Prakash Srivastava und 10 weiteren Autor:innen. Beteiligte Einrichtung: Life Sciences Institute, University of Michigan, Ann Arbor, MI, United States. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 203 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Oxidation and reduction are vital for keeping life through several prime mechanisms, including respiration, metabolism, and other energy supplies. Mitochondria are considered the cell’s powerhouse and use nutrients to produce redox potential and generate ATP and H 2 O through the process of oxidative phosphorylation by operating electron transfer and proton pumping. Simultaneously, mitochondria also produce oxygen free radicals, called superoxide (O 2 − ), non-enzymatically, which interacts with other moieties and generate reactive oxygen species (ROS), such as hydrogen peroxide (H 2 O 2 ), peroxynitrite (ONOO−), and hydroxyl radical (OH − ). These reactive oxygen species modify nucleic acids, proteins, and carbohydrates and ultimately cause damage to organs. The nutrient-sensing kinases, such as AMPK and mTOR, function as a key regulator of cellular ROS levels, as loss of AMPK or aberrant activation of mTOR signaling causes ROS production and compromises the cell’s oxidant status, resulting in various cellular injuries. The increased ROS not only directly damages DNA, proteins, and lipids but also alters cellular signaling pathways, such as the activation of MAPK or PI3K, the accumulation of HIF-1α in the nucleus, and NFkB-mediated transcription of pro-inflammatory cytokines. These factors cause mesenchymal activation in renal endothelial cells. Here, we discuss the biology of redox signaling that underlies the pathophysiology of diabetic renal endothelial cells.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Life Sciences Institute, University of Michigan, Ann Arbor, MI, United States.
- Department of Pediatrics, Yale University School of Medicine, New Haven, CT, United States.
- Vascular Biology and Therapeutic Program, Yale University School of Medicine, New Haven, CT, United States.
- Department of Pathology, Yale School of Medicine, Yale University, New Haven, CT, United States.
- Department of Pharmaceutical Technology, Paavai Engineering College, Namakkal, Tamil Nadu, India.
- Department of Cellular Biology and Anatomy, Augusta University, Augusta, GA, United States.
Förderung
- NIDDK NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Srivastava, S. P., Kopasz-Gemmen, O., Thurman, A., Rajendran, B. K., Selvam, M. M., Kumar, S., Srivastava, R., Suresh, M. X., Kumari, R., Goodwin, J. E., & Inoki, K. (2025). The molecular determinants regulating redox signaling in diabetic endothelial cells. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1563047
Vancouver
Srivastava SP, Kopasz-Gemmen O, Thurman A, Rajendran BK, Selvam MM, Kumar S, et al. The molecular determinants regulating redox signaling in diabetic endothelial cells. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1563047
BibTeX
@article{Srivastava2025,
author = {Srivastava, Swayam Prakash and Kopasz-Gemmen, Olivia and Thurman, Aaron and Rajendran, Barani Kumar and Selvam, M Masilamani and Kumar, Sandeep and Srivastava, Rohit and Suresh, M Xavier and Kumari, Reena and Goodwin, Julie E and Inoki, Ken},
title = {The molecular determinants regulating redox signaling in diabetic endothelial cells},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1563047}
}
EUVIMED